{"url_path":"/sec/avbp/8-k/2026-06-22/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1868279/0001104659-26-076352-index.html","accession_number":"0001104659-26-076352","cik":"0001868279","ticker":"AVBP","issuer_name":"ArriVent BioPharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1868279/0001104659-26-076352-index.html","primary_entity_key":"0001868279","primary_entity_name":"ArriVent BioPharma, Inc."},"word_count":307,"has_tables":true,"body_markdown":"false\n0001868279\n\n0001868279\n\n2026-06-18\n2026-06-18\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES** \n\n**SECURITIES AND EXCHANGE COMMISSION** \n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT** \n\n**Pursuant to Section 13 or 15(d)** \n\n**of the Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported):\n**June 18, 2026**\n\n \n\n**ARRIVENT BIOPHARMA, INC.** \n\n(Exact name of registrant as specified in its\ncharter)\n\n \n\n**Delaware**\n \n**001-41929**\n \n**86-3336099**\n\n(State\nor other jurisdiction\n\nof incorporation)\n \n(Commission\nFile Number)\n \n(IRS\nEmployer\n\nIdentification No.)\n\n \n\n**18 Campus Boulevard, Suite 100**\n\n**Newtown Square, PA**\n\n \n**19073**\n\n(Address\nof principal executive offices)\n \n(zip\ncode)\n\n \n\nRegistrant’s telephone number, including\narea code: **(628) 277-4836**\n\n \n\n**N/A** \n\n**(Former name or former\naddress, if changed since last report.)**\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written communications pursuant to Rule 425 under the Securities\nAct (17 CFR 230.425)\n\n \n\n¨Soliciting material pursuant to Rule 14a-12 under the Exchange\nAct (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement communications pursuant to Rule 14d-2(b) under\nthe Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name of each exchange\non which registered**\n\n**Common Stock,\n$0.0001 par value per share**\n \n**AVBP**\n \n**The\nNasdaq Stock Market LLC**\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (17 CFR §240.12b-2).\n\n \n\nEmerging Growth Company x\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}